New research led by Mass General Brigham investigators suggests that the Bacillus Calmette-Guérin (BCG) vaccine – which is delivered through the skin to prevent tuberculosis – may remodel the human brain’s immune environment, offering a potential biological explanation for previously observed associations between BCG vaccination and lower Alzheimer’s disease risk.